XML 59 R45.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Restructuring Costs (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Restructuring Cost and Reserve [Line Items] |
Restructuring and Related Costs [Table Text Block] | The following table summarizes the activity of our February 2021 plan restructuring reserves (in millions):
|  | 2023 |  | 2022
|  | Life Science |  | Clinical Diagnostics |  | Total |  | Life Science |  | Clinical Diagnostics |  | Total
Balances as of January 1 |  | $ | 1.9 |  |  | $ | 29.7 |  |  | $ | 31.6 |  |  | $ | 5.2 |  |  | $ | 41.9 |  |  | $ | 47.1 |
Adjustment to expense |  | — |  |  | 2.1 |  |  | 2.1 |  |  | 1.1 |  |  | 3.1 |  |  | 4.2 |
Cash payments |  | (1.7) |  |  | (19.4) |  |  | (21.1) |  |  | (4.1) |  |  | (12.7) |  |  | (16.8) |
Foreign currency adjustments |  | — |  |  | 0.4 |  |  | 0.4 |  |  | (0.3) |  |  | (2.6) |  |  | (2.9) |
Balances as of December 31 |  | $ | 0.2 |  |  | $ | 12.8 |  |  | $ | 13.0 |  |  | $ | 1.9 |  |  | $ | 29.7 |  |  | $ | 31.6 |
Management approved three new restructuring plans in February 2023, June 2023, and October 2023 to implement identified opportunities to further streamline and improve operating performance. Our February 2023 plan was implemented in phases and is substantially complete as of December 31, 2023. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. From February 2023 to December 31, 2023, total restructuring-related expenses were $14.2 million, representing estimated termination benefits to employees. The following table summarizes the activity of our February 2023 plan restructuring reserves (in millions):
|  | Life Science |  | Clinical Diagnostics |  | Total
Balances as of January 1, 2023 |  | $ | — |  |  | $ | — |  |  | $ | — |
Charged to expense - employee termination benefits |  | 2.7 |  |  | 11.5 |  |  | 14.2 |
Cash payments |  | (1.8) |  |  | (6.0) |  |  | (7.8) |
Foreign currency adjustments |  | 0.1 |  |  | 0.4 |  |  | 0.5 |
Balances as of December 31, 2023 |  | $ | 1.0 |  |  | $ | 5.9 |  |  | $ | 6.9 |
Our June 2023 restructuring plan is substantially complete as of December 31, 2023. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. From June 2023 to December 31, 2023, total restructuring-related expenses were $8.1 million, representing estimated termination benefits to employees. The following table summarizes the activity of our June 2023 plan restructuring reserves (in millions):
|  | Life Science |  | Clinical Diagnostics |  | Total
Balances as of January 1, 2023 |  | $ | — |  |  | $ | — |  |  | $ | — |
Charged to expense - employee termination benefits |  | 4.0 |  |  | 4.1 |  |  | 8.1 |
Cash payments |  | (3.5) |  |  | (2.9) |  |  | (6.4) |
Foreign currency adjustments |  | — |  |  | 0.1 |  |  | 0.1 |
Balances as of December 31, 2023 |  | $ | 0.5 |  |  | $ | 1.3 |  |  | $ | 1.8 |
Our October 2023 restructuring plan is expected to be substantially complete in early 2024. From October 2023 to December 31, 2023, total restructuring-related expenses were $3.5 million, representing estimated termination benefits to employees. The following table summarizes the activity of our October 2023 plan restructuring reserves (in millions):
|  | Life Science |  | Clinical Diagnostics |  | Total
Balances as of January 1, 2023 |  | $ | — |  |  | $ | — |  |  | $ | — |
Charged to expense - employee termination benefits |  | 2.7 |  |  | 0.8 |  |  | 3.5 |
Cash payments |  | (1.2) |  |  | (0.3) |  |  | (1.5) |
Foreign currency adjustments |  | — |  |  | 0.1 |  |  | 0.1 |
Balances as of December 31, 2023 |  | $ | 1.5 |  |  | $ | 0.6 |  |  | $ | 2.1 |
Combined, the liability of $23.8 million as of December 31, 2023 consisted of $22.9 million recorded in Accrued payroll and employee benefits and $0.9 million recorded in Other long-term liabilities in the consolidated balance sheets. Restructuring-related expense is allocated in the consolidated statements of income (loss) as follows (in millions):
|  | Year ended December 31,
|  | 2023 |  | 2022 |  | 2021
Cost of goods sold |  | $ | 3.9 |  |  | $ | 1.1 |  |  | $ | 25.0 |
Selling, general and administrative expense |  | 17.5 |  |  | 3.0 |  |  | 26.1 |
Research and development expense |  | 6.5 |  |  | 0.1 |  |  | 13.3 |
Restructuring expense |  | $ | 27.9 |  |  | $ | 4.2 |  |  | $ | 64.4 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 + Details
Name: | us-gaap_RestructuringCostAndReserveLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 + Details
Name: | us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration